When combining the SARS-CoV variant groups, clinical signs were significantly lower in PBS controls compared to the SAB-185-treatment group on D2-12 ( Figure 4 B) and highly significant (p < 0.001) on D4-12 ( Figures 4 B and 4C).
The average clinical score for PBS control animals challenged with Δ144-146 and Beta was lower compared to SAB-185-treated animals in these groups but did not reach statistical significance ( Figures 4 G and 4K).
While hamsters in the PBS control groups challenged with Alpha and Δ144-146 variants experienced weight loss, the difference failed to reach statistical significance compared to SAB-185-treated hamsters challenged with the same variants ( Figures 3 F–3I).